$83.03
+1.22 (+1.49%)
Performance
1D
—
1W
—
1M
—
3M
+33.64%
6M
+31.90%
1Y
+109.78%
YTD
+9.57%
Open$82.76
Previous Close$81.81
Day High$84.15
Day Low$82.06
52W High$95.32
52W Low$34.34
Volume—
Avg Volume580.1K
Market Cap6.16B
P/E Ratio—
EPS$-4.22
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$73.88
Above
SMA 200
$52.13
Above
RSI (14)
48.1
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
23 analysts
Price Target
+22.3% upside
Current
$83.03
$83.03
Target
$101.57
$101.57
$78.76
$101.57 avg
$153.22
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 911.35M | 871.62M | 948.06M |
| Net Income | -243,438,723 | -174,175,180 | -203,637,440 |
| Profit Margin | -26.7% | -20.0% | -21.5% |
| EBITDA | -267,934,128 | -228,786,100 | -261,593,713 |
| Free Cash Flow | -101,879,133 | -97,401,406 | -128,866,616 |
| Rev Growth | +22.2% | +5.3% | +12.3% |
| Debt/Equity | 0.88 | 0.85 | 0.60 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |